ASH 2020 | Bleeding and thrombotic complications in CAR T-cell therapy for B-cell malignancies
Surbhi Sidana, MD, Stanford University, Stanford, CA, shares the details of a retrospective study of bleeding and thrombotic complications associated with CAR T-cell therapy for B-cell malignancies. How these complications are related to side effects such as cytokine release syndrome (CRS), immune effector-cell associated neurotoxicity syndrome (ICANS), and consumption coagulopathy was also investigated. 130 B-ALL and diffuse large B-cell lymphoma patients were analyzed, and grade ≥2 complications recorded. 9.2% and 6.2% of patients showed bleeding and thrombotic complications, respectively. CRS occurrence was not associated with these complications, but ICANS was associated with bleeding, thrombosis, hypofibrinogenemia, and prolonged prothrombin time. It appears that systemic coagulopathy and ICANS occurrence coincide; the possibility of ICANS being a sequela of vascular dysfunction requires further investigation. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
